Non-IgG Therapeutic Antibodies Engineering

The immunogenicity and applicability of non-parental antibodies are considerably enhanced by chimeric antibodies. Chimeric technologies are required to create engineered non-IgG antibodies. Consider IgA as an example. The IgA Fc receptor, or FcRI, effectively initiates cytotoxicity. According to reports, a chimeric secretory IgA (SIgA) was created to fight the H5N1 avian influenza by cloning the […]